CYP17A1 - an overview | ScienceDirect Topics
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer | British Journal of Cancer
Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective - ScienceDirect
Androgen receptor antagonism and impact on inhibitors of androgen synthesis in prostate cancer therapy - Njar - Translational Cancer Research
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer | Scientific Reports
P450 Signaling | CYP450
Abiraterone, CYP17 inhibitor Abiraterone (CB-7598)-Xcessbio Biosciences Inc
Abiraterone (Zytiga): Mechanism of Zytiga
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
Abiraterone Acetate | ≥99%(HPLC) | Selleck | P450 (e.g. CYP17) inhibitor
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer
CYP17 inhibition as a hormonal strategy for prostate cancer | Nature Reviews Urology
CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials Cao Q, Bai P, Shi D, Liao J, Shi H, Xing Y, Chen K, Zhang X -
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
APExBIO - Abiraterone|Potent CYP17 inhibitor|CAS# 154229-19-3
CYP17 inhibition as a hormonal strategy for prostate cancer | Nature Reviews Urology
Mechanisms of resistance to CYP17 inhibitors. Androgen receptor (AR)... | Download Scientific Diagram
CYP17A1 inhibitor - Wikipedia
CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials Cao Q, Bai P, Shi D, Liao J, Shi H, Xing Y, Chen K, Zhang X -
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature. - Abstract - Europe PMC
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
PDF) CYP17 inhibitors - Abiraterone, C17,20-lyase inhibitors and multi-targeting agents
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
